Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06990880 · ClinicalTrials.gov registry record · Phase 1
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
A Phase 1 study of Neoplasms Prostate, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
- 5
- Study locations
NCT06990880 is a Phase 1 study of Neoplasms Prostate that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 85 participants, below the 3,094-participant average among 6 other Neoplasms Prostate trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT06990880, a Phase 1 study of Neoplasms Prostate, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
- 5
- Study locations
Study Summary
The goal of the study is to evaluate how safe and how well the body handles GSK5458514 when administered in participants with prostate cancer. The study will be conducted in two parts - Part 1 (dose escalation phase) and Part 2 (dose expansion phase).
Conditions Studied
Interventions
- DRUG GSK5458514
Study Locations (5)
Other
- GSK Investigational Site - Tokyo
- GSK Investigational Site - Tokyo
Colorado
- GSK Investigational Site - Denver
Tennessee
- GSK Investigational Site - Nashville
Quebec
- GSK Investigational Site - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2025-06-12 |
| Est. Completion | 2028-08-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06990880
The ClinicalTrials.gov registry entry for NCT06990880 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,094-participant average among 6 other Neoplasms Prostate trials with a reported enrollment target (97% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasms Prostate appearing as the primary indexed condition, and to 1 intervention - of which GSK5458514 is the first listed.
NCT06990880 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Other, Colorado, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06990880 about?
NCT06990880 is a clinical study titled "A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer". The goal of the study is to evaluate how safe and how well the body handles GSK5458514 when administered in participants with prostate cancer. The study will be conducted in two parts - Part 1 (dose escalation phase) and Part 2 (dose expansion phase).
What is the current status of trial NCT06990880?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2025-06-12. Estimated completion is 2028-08-09.
What conditions does trial NCT06990880 study?
This clinical trial studies the following conditions: Neoplasms Prostate.
What interventions are being tested in trial NCT06990880?
The interventions under investigation include: GSK5458514 (DRUG).
Who is sponsoring clinical trial NCT06990880?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06990880 being conducted?
This trial has 5 study locations across Colorado, Tennessee, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms Prostate
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
RECRUITING · Phase 1
-
MRI/Ultrasound Fusion Guided Prostate Cryotherapy
RECRUITING
-
MRI/Ultrasound Fusion Guided Laser Ablation of Prostate Cancer
RECRUITING
-
Investigation of Impact of AI on Prostate Cancer Workflow
RECRUITING · NA
-
Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
COMPLETED · Phase 4
-
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.